Published by Unseen Progress, an independent publisher of caregiver research. Last reviewed 2026-05-10. Part of the tic disorders research overview.
Short answer. The American Academy of Neurology / Tourette Association practice guideline (Pringsheim et al., 2019) places medication after Comprehensive Behavioural Intervention for Tics (CBIT) for most children, reserved for moderate-to-severe tics that persist despite behavioural work or when CBIT is unavailable. When medication is indicated, alpha-agonists (clonidine, guanfacine) are typically tried first, with antipsychotics (aripiprazole, risperidone, and in some regions tetrabenazine, haloperidol, or pimozide) reserved for cases that do not respond.
Most childhood tics do not warrant medication. The AAN guideline and the AACAP practice parameter (Murphy et al., 2013) converge on a functional-impact threshold rather than a tic-count threshold: medication is considered when tics are causing meaningful disruption to school performance, social functioning, sleep, physical comfort, or emotional wellbeing — and behavioural treatment has been tried, is unavailable, or is insufficient.
The framing matters. A child with conspicuous tics whose school day, friendships, and sleep are essentially intact does not meet the threshold; a child with subtler tics that are causing daily pain, peer rejection, or sleep disruption may. Severity, in this guideline, is functional, not visual.
Clonidine and guanfacine are alpha-2 adrenergic agonists originally developed as antihypertensives. In tic disorders they are used at low doses for their secondary effect on tic frequency, with the additional benefit that they treat ADHD symptoms — relevant because roughly sixty percent of children with Tourette syndrome also have ADHD (Murphy et al., 2013).
Scahill and colleagues' pharmacological work established the empirical case for alpha-agonists in this population, and the AAN guideline (Pringsheim et al., 2019) flags them as the typical first-line medication choice when the comorbid picture includes ADHD, which it usually does. Effect sizes for tic reduction are modest — measurable but not large — and the side-effect profile is generally tolerable, with sedation and lowered blood pressure being the most common issues.
Two practical points. First, alpha-agonists are usually titrated slowly, with effects visible over weeks rather than days. Second, the same logic about waxing and waning applies to medication trials as to behavioural ones — judging an alpha-agonist by a single bad week early in the titration window will systematically misread its effect.
Aripiprazole and risperidone are the antipsychotics most commonly used in current practice for moderate-to-severe tics that have not responded to behavioural work and alpha-agonists. Older agents — haloperidol, pimozide — and the dopamine-depleter tetrabenazine remain in use in some regions and for treatment-refractory cases.
The AAN guideline (Pringsheim et al., 2019) treats antipsychotic use as a higher-evidence option for tic reduction with a meaningfully larger effect size than alpha-agonists, balanced against a more demanding side-effect profile: weight gain and metabolic changes are the most common ongoing concerns; sedation and movement effects are watched for. The guideline does not rank specific antipsychotics against each other definitively — choice is typically driven by the prescriber's experience, the child's comorbidities, and the side-effect profile most acceptable to the family.
The decision to escalate from alpha-agonist to antipsychotic is one of the most consequential in tic-disorder care, and the AAN guideline is explicit that it should be made on the basis of demonstrated insufficient response, not on the basis of severity alone.
The single most preventable error in tic-medication management is making escalation or change decisions during a waxing phase. Tics fluctuate naturally over weeks to months, independently of treatment (Murphy et al., 2013; Bloch & Leckman, 2009). A medication trial inside a single bad fortnight cannot be evaluated on a single bad fortnight.
The practical implication is that medication decisions should be made from at least eight to twelve weeks of severity data, not from the last clinic visit's recollection. A family bringing a structured severity record to the prescribing clinician changes the conversation: instead of debating whether the last few weeks felt worse, the trend across two waxes and a wane is visible, and the question of whether the medication is actually working becomes answerable.
Unnecessary medication changes driven by misinterpreted fluctuation are, in the literature on this market, one of the most common preventable mistakes (Murphy et al., 2013).
The AAN guideline reviewed evidence on a range of alternative interventions and reached cautious conclusions: there is preliminary evidence for some agents, insufficient evidence for most, and active concern about marketed elimination diets and supplements promoted as cures. The Tourette Association's family-facing guidance is consistent — anchor to the established evidence base; treat unproven claims as hypotheses, not plans.
For a family weighing the medication question:
1. Confirm functional impact, not visual severity, is what is driving the consideration. If the child's day is essentially intact, the threshold is probably not met. 2. Try CBIT first when it is available, especially for children old enough to engage with awareness and competing-response work. 3. Do not initiate or change medication during a waxing phase. Bring eight to twelve weeks of severity data to the appointment. 4. If alpha-agonists are tried, give the titration eight to twelve weeks before judging the effect. Sedation and blood-pressure changes are typical and usually tolerable. 5. Treat the alpha-agonist-to-antipsychotic step as a meaningful escalation. The AAN guideline supports it for insufficient response, not for severity alone.
---
Unseen Progress publishes long-form caregiver research and builds research-backed daily trackers for the families covered. See the full tic disorders research overview for the complete framework.